Co-Diagnostics, Inc. Cash And Cash Equivalents At Carrying Value

• Co-Diagnostics, Inc. showed an increase of +304.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
• This data is from Co-Diagnostics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2016: $1.5 thousand | Q3 2016: $53.4 thousand | Q1 2017: $496.5 thousand | Q2 2017: $116.8 thousand | Q3 2017: $4.63 million | Q4 2017: $3.53 million | Q1 2018: $2.54 million | Q2 2018: $1.53 million | Q3 2018: $2.18 million | Q1 2019: $5.41 million | Q2 2019: $3.86 million | Q3 2019: $2.54 million | Q1 2020: $17.37 million | Q2 2020: $18.55 million | Q3 2020: $21.23 million | Q1 2021: $57.79 million | Q2 2021: $70.27 million | Q3 2021: $82.66 million | Q1 2022: $97.42 million | Q2 2022: $86.05 million | Q3 2022: $81.51 million | Q1 2023: $6.36 million | Q2 2023: $13.83 million | Q3 2023: $10.24 million | Q1 2024: $23.10 million | Q2 2024: $13.86 million | Q3 2024: $10.80 million | Q1 2025: $1.90 million | Q2 2025: $11.12 million | Q3 2025: $11.44 million.
• Over the full 11 years of available data (2015 to 2025), Co-Diagnostics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 35,056.4%.
• Historical annual values: Fiscal year 2025: $11.88 million | Fiscal year 2024: $2.94 million | Fiscal year 2023: $14.92 million | Fiscal year 2022: $22.97 million | Fiscal year 2021: $88.61 million | Fiscal year 2020: $42.98 million | Fiscal year 2019: $893.1 thousand | Fiscal year 2018: $950.2 thousand | Fiscal year 2017: $3.53 million | Fiscal year 2016: $998.7 thousand | Fiscal year 2015: $33.8 thousand.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026